Loading
companiesCompany
Shanghai Juncell Therapeutics
Shanghai Juncell Therapeutics is a China-based cell therapy company running 2 late-stage cancer trials of GC101 TIL in melanoma and non-small-cell lung cancer.
Overview
Shanghai Juncell Therapeutics, based in Shanghai, China, is a cell therapy company. Juncell Therapeutics is a biotech enterprise focused on research, development and commercialisation of innovative cell therapies for solid tumours, using tumour-infiltrating lymphocyte (TIL) technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GC101 TIL in melanoma and non-small-cell lung cancer. The largest, NCT06703398 (A Study of GC101 TIL in Advanced Melanoma), plans to enrol 98 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#330of 1244 companies, score 12
- phase 1/2 +1
- targets +6
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 3 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2019
Phase 2TIL therapy
GC101 TIL is an experimental tumour-infiltrating lymphocyte therapy from Shanghai Juncell Therapeutics in phase 2 trials for melanoma, aimed at PD-1 and BRAF.
Similar pages
- TargetMEK1/2
Shares GC101 TIL, Melanoma, Non-small-cell lung cancer.
- TreatmentDacarbazine
cancers
drugs
Phase 2TIL therapy